Search

Your search keyword '"Paul Carle"' showing total 1,011 results

Search Constraints

Start Over You searched for: Author "Paul Carle" Remove constraint Author: "Paul Carle"
1,011 results on '"Paul Carle"'

Search Results

1. Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program

8. A Solve-RD ClinVar-based reanalysis of 1522 index cases from ERN-ITHACA reveals common pitfalls and misinterpretations in exome sequencing

9. Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials

10. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial

13. Cav1.4 calcium channels control cytokine production by human peripheral TH17 cells and psoriatic skin-infiltrating T cells

15. Mastocytosis

21. The prevalence of skin diseases in Greece, impact on quality of life and stigmatization:A population-based survey study

22. The vIGA-AD scale for atopic dermatitis:Uptake in the past 5 years and position of the International Eczema Council

23. Noninferiority of 16-Week vs 8-Week Guselkumab Dosing in Super Responders for Maintaining Control of Psoriasis: The GUIDE Randomized Clinical Trial.

24. The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): The development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis

26. Human neutrophils drive skin autoinflammation by releasing interleukin (IL)-26

28. The prevalence of osteoporosis is low in adult cutaneous mastocytosis patients

29. Correction: Landscape of mast cell populations across organs in mice and humans

30. Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program

31. Deucravacitinib in plaque psoriasis: 2-year safety and efficacy results from the phase III POETYK trials

34. Pimecrolimus in atopic dermatitis: Consensus on safety and the need to allow use in infants

39. Large International Validation of ABSIS and PDAI Pemphigus Severity Scores

43. Deucravacitinib in Plaque Psoriasis: Maintenance of Response Over 3 Years in the Phase 3 POETYK PSO-1 and PSO-2 Trials

44. The vIGA‐AD scale for atopic dermatitis: uptake in the past five years and position of the International Eczema Council

45. The burden of skin disease in Europe

48. Price variability of TNF‐α inhibitor biosimilars among European countries.

50. Freedom from disease in plaque psoriasis: Comparing the perceived importance of voting round 2 statements from a Delphi consensus of patients, physicians and nurses

Catalog

Books, media, physical & digital resources